Latest news newssearch boxGO All Ad hoc Other 21 Oct 2020 Idorsia successfully completes capital increase with gross proceeds of CHF 535.5 million 20 Oct 2020 Idorsia announces the results of its rights offering in the context of the capital increase 08 Oct 2020 Idorsia announces capital increase to prepare for the launch of daridorexant and further fund its diversified pipeline 02 Sep 2020 Janssen announces the presentation of additional ponesimod data at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting 02 Sep 2020 Idorsia assigns and transfers agreement with ReveraGen to Santhera 31 Aug 2020 Idorsia selects Syneos Health as commercialization partner to launch daridorexant in the United States 28 Aug 2020 Daridorexant Phase 3 results in insomnia presented at SLEEP 2020 13 Aug 2020 Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020 06 Aug 2020 Idorsia Japan confirms daridorexant dose response in Japanese patients with insomnia – preparation for a local registration program advancing 23 Jul 2020 Idorsia announces financial results for the first half 2020 16 Jul 2020 Idorsia establishes US commercial operations and leadership team 06 Jul 2020 Idorsia announces positive results in the second Phase 3 study of daridorexant 20 May 2020 Idorsia successfully completes the offering of new shares thereby securing funding for the company’s growth plan 19 May 2020 Idorsia launches an offering of new shares to fund the company’s growth plan 13 May 2020 Idorsia holds its third Annual General Meeting of Shareholders 12 May 2020 Neurocrine Biosciences exercises option to license Idorsia's novel treatment for rare pediatric epilepsy 23 Apr 2020 Idorsia announces financial results for the first quarter 2020 20 Apr 2020 Idorsia announces positive results in the first Phase 3 study of daridorexant with improved overall sleep and daytime performance of patients with insomnia 02 Apr 2020 Idorsia issues Notice of the 2020 Annual General Meeting of Shareholders 19 Mar 2020 Janssen announces submission of New Drug Application to the U.S. FDA for ponesimod for treatment of adults with relapsing multiple sclerosis 1 2 3 4 5 6 7 8